Longevity Treatments Spread Lifespans Rather Than Equalizing Them
Dietary restriction, rapamycin, and metformin extend average lifespan but increase variation in age-at-death, challenging the 'squaring the curve' ideal.
Resumen
A re-analysis of vertebrate longevity data finds that three major lifespan-extending interventions — dietary restriction, rapamycin, and metformin — raise average age-at-death but simultaneously increase variance in when individuals die. This contradicts the popular goal of 'squaring the survival curve,' where everyone ideally lives long and dies within a narrow window. While the coefficient of variation (SD relative to the mean) stays roughly constant, absolute variance grows. The findings suggest these treatments proportionally reduce both age-dependent and age-independent mortality rates in a Gompertz model, meaning longer average life comes bundled with greater spread — not a more uniform lifespan across individuals.
Resumen detallado
A central aspiration in geroscience is not merely to extend average lifespan but to ensure that most individuals reach old age — an ideal captured by the concept of 'squaring the survival curve,' where the survival curve drops steeply at a late age rather than tapering gradually. This new analysis challenges whether current leading interventions actually achieve that goal.
Researchers at the University of Sydney re-analyzed a published meta-analysis of vertebrate longevity data examining three geroprotective interventions: dietary restriction (DR), rapamycin (an mTOR inhibitor and DR-mimetic), and metformin (another DR-mimetic, though less consistently effective). Rather than focusing solely on mean age-at-death, they examined what happened to variance and the coefficient of variation (CV) — standard deviation relative to the mean.
The key finding: all three treatments increased absolute variance in age-at-death on average, while the CV remained largely unchanged. In plain terms, when these interventions extend life, they do not compress the spread of death ages — they expand it proportionally. Some individuals benefit enormously; others gain little. The distribution widens rather than tightens.
Mechanistically, the authors note this pattern is consistent with the interventions proportionally reducing both the age-dependent (Gompertz slope) and age-independent (baseline hazard) mortality parameters simultaneously — a mathematical outcome that preserves relative variation even as the mean shifts upward.
These results carry important implications for both research and clinical expectations. Interventions celebrated for extending average lifespan may be masking highly heterogeneous individual responses. The equitable vision of everyone living a long, similarly-timed life remains unachieved by current tools. Future research should prioritize identifying who benefits most and why, and whether combination strategies or personalized approaches can narrow the outcome gap.
Hallazgos clave
- Dietary restriction, rapamycin, and metformin all increase absolute variance in age-at-death, not just the mean.
- The coefficient of variation (SD/mean) remains unchanged, meaning relative variability stays constant across treatments.
- No evidence supports 'squaring the survival curve' — lifespan gains are accompanied by proportional spread in death ages.
- Results are consistent with treatments proportionally reducing both age-dependent and age-independent Gompertz mortality parameters.
- Metformin showed less consistent efficacy in extending mean lifespan compared to DR and rapamycin.
Metodología
This is a re-analysis of a previously published vertebrate meta-analysis dataset examining dietary restriction, rapamycin, and metformin. The authors assessed effects on variance and coefficient of variation in age-at-death, and interpreted results through a Gompertz mortality modeling framework.
Limitaciones del estudio
The study relies on re-analyzing existing vertebrate (largely animal model) data, limiting direct human applicability. Only three interventions were examined, and the meta-analytic dataset may have heterogeneity in study design, species, and dosing. Abstract-only access means methodological details of the re-analysis cannot be fully evaluated.
¿Te ha gustado este resumen?
Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.
Introduce tu correo electrónico para suscribirte:
